Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing (Jul 30, 2025) by James Waldron. Summary Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra The GLP-1 drug, dubbed SYH2086, has been developed by China’s CSPC Pharmaceutical. Preclinical

Novartis puts $1B on the line to court preclinical biotech Matchpoint (July 24, 2025) by Gabrielle Masson. Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult to treat. The exclusive option and licensing pact covers the development and commercialization

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal (July 24, 2025) by Gabrielle Masson. Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small-molecule drug class. The pact’s potential value includes an undisclosed upfront payment amount and equity investment in the